Home

S.Korea targets 40m extra vaccine doses

AAP
President Moon Jae-in shows a vial of the Novavax vaccine produced by S. Korean firm SK Bioscience.
Camera IconPresident Moon Jae-in shows a vial of the Novavax vaccine produced by S. Korean firm SK Bioscience.

South Korea is in talks to purchase 40 million doses of a coronavirus vaccine developed by Novavax, its local manufacturer says.

The deal, if agreed, will boost supply of COVID-19 vaccines in the country to 146 million doses, more than enough for its 52 million residents, and comes as Seoul prepares to start mass inoculations in February.

SK Bioscience, which also manufactures AstraZeneca's vaccine, is working on a technology transfer deal with Novavax which will allow it to produce and sell vaccines on its own.

A deal with the South Korean government could be its first direct supply deal.

Get in front of tomorrow's news for FREE

Journalism for the curious Australian across politics, business, culture and opinion.

READ NOW

South Korea's President Moon Jae-in visited SK's offices on Wednesday and said the agreement raised the possibility of securing additional doses of vaccines.

The country has already secured 106 million doses from global vaccine supply facility COVAX and Western drugmakers including Pfizer, Moderna, AstraZeneca and Johnson & Johnson.

Moon's visit comes as his administration faces criticism for not taking the necessary steps to achieve its goal of reaching herd immunity through mass vaccinations by November.

The government had laid out a timeline that calls for vaccinations of key individuals to begin in February, with 32-to-36 million people vaccinated by September.

South Korea reported 404 new coronavirus cases on Tuesday, bringing the country's tally to 73,518 cases, with 1300 deaths.

Get the latest news from thewest.com.au in your inbox.

Sign up for our emails